Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

In this case report, two patients with coexisting systemic lupus erythematous and neuromyelitis optica spectrum disorder achieved remission of SLE activity using an anti-CD19 monoclonal antibody.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

Finasteride can cause lasting sexual and mood issues even after stopping the drug.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

This study found that neurosteroids and benzodiazepines decrease network excitability in neuronal cultures, with specific long-term depressive effects on inhibitory neurons.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

This review discusses the complex interplay between the nervous system and skin conditions, highlighting various treatment strategies, but reports no new research findings.

This case report highlights a unique instance where the use of naproxen was associated with concurrent eosinophilic pneumonitis and diffuse alveolar hemorrhage, conditions not previously linked to NSAIDs.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that melatonin-loaded nanoparticles improved antidepressant effects and HPA axis regulation in pinealectomized rats, compared to free melatonin, through controlled-release properties.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

In this narrative review, the researchers reported that the overall safety profile of drugs used for treating spondyloarthritis is generally good, with serious adverse events being rare, but emphasized the need for rheumatologists to tailor treatments and closely monitor patients for potential adverse events.

This report describes a case of a patient with Sjogren's syndrome who experienced multiple episodes of aseptic meningitis linked to taking trimethoprim-sulfamethoxazole and trimethoprim alone.

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

In this animal study, finasteride significantly improved autism-like symptoms in rats by reversing biochemical markers and enhancing behaviors, potentially due to its antioxidant and anti-androgen effects.

This study developed solid lipid nanoparticles for effective delivery of shRNA-encoding plasmids, showing reduced 5α-reductase levels in DU-145 cells without significant cytotoxicity.

This study found that the 5α-reductase inhibitor finasteride affected phasic and tonic GABA A receptor-mediated currents differently in the thalamic reticular and ventrobasal nuclei of mice, suggesting endogenous neurosteroid modulation of these receptors.

In this pilot study, no significant differences were observed between memantine and placebo groups in young adults with Down syndrome on the primary memory outcomes, but some improvement was noted in a secondary measure.

This research overview discusses Post-Finasteride Syndrome, presenting data from an FDA database, but it does not report any new clinical findings.

This study found that finasteride impaired stress reactivity and reduced exploratory and impulsive behaviors in rats, potentially by altering the hypothalamus-pituitary-adrenal axis function.

This study found that naltrexone did not significantly reduce hair pulling in adults with trichotillomania compared to placebo, although it improved cognitive flexibility.